RecruitingPhase 3

Semaglutide for the Treatment of Glucose Intolerance in Women With Prior Gestational Diabetes

Belgium252 participantsStarted 2023-09-14

Plain-language summary

Gestational diabetes (GDM) is an important contributor to the increasing prevalence of type 2 diabetes (T2DM). Women with glucose intolerance in early postpartum are a particularly high-risk group with about 50% who will develop T2DM within 5 years after the delivery. Moreover, women with a history of GDM progress more rapidly to T2DM compared to women with similarly elevated glucose levels. Early intervention after the index pregnancy is therefore crucial to prevent T2DM. With the SERENA project, the investigators aim to reduce the risk to develop T2DM with the long-acting GLP-1 agonist semaglutide in women with a recent history of GDM and glucose intolerance in early postpartum.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Voluntary written informed consent of the participant has been obtained prior to any screening procedures
✓. Use of highly effective methods of birth control
✓. History of GDM (diagnosed with 2013 WHO criteria 24-32 weeks of pregnancy) and glucose intolerance 6-24 weeks postpartum (based on the ADA criteria)
✓. Needs to be able to understand and speak Dutch, French or English

What they're measuring

type 2 diabetes

Timeframe: by 160 weeks

Trial details

NCT IDNCT05569772

SponsorUniversitaire Ziekenhuizen KU Leuven

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2029-06

Contact for this trial

Katrien Benhalima, MD PhD

16340614 katrien.benhalima@uzleuven.be

View on ClinicalTrials.gov More Glucose Intolerance After a Recent History of Gestational Diabetes trials